查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1500244

藥物基因體學市場：按產品、技術、適應症和應用分類 - 2024-2030 年全球預測

Pharmacogenomics Market by Product (Consumables, Kits & Reagents, Services), Technology (DNA Sequencing, Electrophoresis, Mass Spectrometry), Indication, Application - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年藥物基因體學市場規模為40.6億美元，2024年將達44.8億美元，2030年將達到82億美元，複合年成長率為10.54%。

藥物基因體學市場涉及影響個體對藥物反應的遺傳變異的研究。藥物基因體學結合了藥理學、基因組學和個人化醫學，根據患者的基因組成定製藥物治療，提高療效並最大限度地減少副作用。 DNA序列測定和分析領域的創新推動了藥物基因體學的進步。向客製化治療方法的轉變增加了對藥物基因組測試的需求。增加對醫療保健尤其是精準醫療的投資是市場的關鍵成長要素。然而，處理遺傳訊息會引發隱私和道德問題。與藥物基因組測試和分析相關的成本阻礙了廣泛採用，這對市場成長構成了挑戰。此外，將藥物基因組資料整合到藥物開發中可以提高藥物功效和安全性，並減少時間和成本。利用人工智慧預測患者對藥物的反應可以改善個人化治療方法並創造市場成長機會。

主要市場統計
基準年[2023] 40.6億美元
預測年份 [2024] 44.8億美元
預測年份 [2030] 82億美元
複合年成長率（%） 10.54%

區域洞察

在美國，在廣泛的研究、大量投資和支持性監管政策的推動下，KEYWORD 已深入臨床實踐。個人化醫療的監管努力和領先生物製藥公司的存在正在促進美洲地區充滿活力的市場動態。在 Horizo​​n Europe 合作計劃和資金籌措的支持下，歐洲地區在藥物基因體學方面正在取得進展。歐洲藥物基因學實施聯盟 (Eu-PIC) 等舉措旨在協調區域臨床實踐。由於醫療保健支出的增加以及對中東醫療保健基礎設施的關注，藥物基因體學越來越受到關注。沙烏地阿拉伯和阿拉伯聯合大公國等國家正在投資基因研究和生物技術，並預計藥物基因體學將成為其醫療保健戰略的關鍵要素。在亞太地區，由於政府在生物技術和醫療改革方面的舉措，中國、印度和日本等主要國家正經歷顯著成長。對國內大型基因組研究和基因檢測公司的投資凸顯了向個人化醫療的策略性舉措，並滿足了消費者對客製化醫療解決方案日益成長的需求。

FPNV定位矩陣

FPNV 定位矩陣對於評估藥物基因體學市場供應商的市場定位至關重要。此矩陣提供了對供應商的全面評估，並檢查了與商務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果，供應商被分為代表其成功程度的四個像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對藥物基因體學市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻，您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他關鍵指標。此外，該分析還提供了對該領域競爭性質的寶貴見解，包括研究時間段的累積、碎片化的優勢以及合併的特徵等因素。有了這些詳細資訊，供應商可以做出更明智的決策並製定有效的策略，以在市場競爭中保持領先地位。

策略分析與建議

策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在藥物基因體學市場中的地位進行全面評估，使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析，以確定核心優勢和需要改進的領域。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病發生率上升和精準醫療需求
      • 加大醫療基礎建設投資
      • 與分子診斷程序相關的技術進步
    • 抑制因素
      • 與研發能力相關的高成本
    • 機會
      • 個人化醫療和消費者基因檢測服務的新興趨勢
      • 增加對研發活動的投資以改善藥物基因體學
    • 任務
      • 缺乏意識和必要的基礎設施
  • 市場區隔分析
    • 技術：聚合酵素鏈鎖反應技術的進步
    • 應用：藥物基因體學在各行業的多樣化應用
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章藥物基因體學市場：依產品

  • 消耗品
  • 套件和試劑
  • 服務

第7章藥物基因體學市場：依技術分類

  • DNA序列分析
  • 電泳
  • 質譜
  • 微陣列
  • 聚合酵素鏈鎖反應

第8章藥物基因體學市場（按適應症）

  • 神經病學
  • 腫瘤學
  • 疼痛管理

第9章藥物基因體學市場：依應用分類

  • 臨床診斷實驗室
  • 臨床研究和藥物發現
  • 個人化醫療

第10章美洲藥物基因體學市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太藥物藥物基因體學市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的藥物基因體學市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • SOPHiA GENETICS 宣布擴大與 CHU de Nimes的業務
    • Diatech Pharmaco Genetics 宣佈建立新的合作夥伴關係，以推進腫瘤學的精確測試
    • MyRx推出虛擬藥物基因檢測諮詢服務
  • 戰略分析和建議

第14章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-742BD5183871

[195 Pages Report] The Pharmacogenomics Market size was estimated at USD 4.06 billion in 2023 and expected to reach USD 4.48 billion in 2024, at a CAGR 10.54% to reach USD 8.20 billion by 2030.

The pharmacogenomics market encompasses the study of genetic variations influencing an individual's response to drugs. Pharmacogenomics combines pharmacology, genomics, and personalized medicine to tailor pharmaceutical treatments to patient's genetic makeup, enhancing efficacy and minimizing adverse effects. Innovations in DNA sequencing and analysis have propelled pharmacogenomics forward. A shift towards tailored therapeutic approaches has heightened the need for pharmacogenomic testing. Rising investment in healthcare, particularly in precision medicine, is a crucial growth driver in the market. However, handling genetic information raises privacy issues and ethical questions. The expense associated with pharmacogenomic testing and analysis can be prohibitive for widespread adoption, challenging the market growth. Moreover, Integrating pharmacogenomic data in drug development can enhance drug efficacy and safety, reducing time and costs. Leveraging AI to predict patient responses to drugs can refine personalized treatment approaches, creating opportunities for market growth.

KEY MARKET STATISTICS
Base Year [2023] USD 4.06 billion
Estimated Year [2024] USD 4.48 billion
Forecast Year [2030] USD 8.20 billion
CAGR (%) 10.54%

Regional Insights

In the U.S., pharmacogenomics has integrated deeply into clinical practices, propelled mainly by extensive research, substantial investments, and supportive regulatory policies. Initiatives by the regulatory authorities toward personalized medicine and the presence of leading biopharmaceutical companies contribute to vibrant market dynamics in the Americas region. The European region is advancing in pharmacogenomics, backed by collaborative projects and funding under Horizon Europe. Initiatives such as the European Pharmacogenetics Implementation Consortium (Eu-PIC) aim to harmonize regional clinical practices. Pharmacogenomics is gaining traction with the Middle East's growing healthcare expenditure and focus on healthcare infrastructure. Countries such as Saudi Arabia and the UAE are investing in genetic research and biotechnology, foreseeing pharmacogenomics as a crucial component of their healthcare strategy. In the APAC region, major countries such as China, India, and Japan are witnessing significant growth driven by government initiatives in biotechnology and healthcare reform. The country's massive genomic studies and investments in genetic testing companies underline a strategic move towards personalized medicine, meeting a growing consumer demand for customized healthcare solutions.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Pharmacogenomics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Rising incidences of chronic diseases and demand for precision medicine
      • Increasing investments for healthcare infrastructures
      • Technological advancements associated with molecular diagnostics procedure
    • Market Restraints
      • High costs associated with research and development proficiencies
    • Market Opportunities
      • Emerging trend of personalized medicines and direct-to-consumer genetic testing services
      • Rising investment in R&D activities to improve pharmacogenomics
    • Market Challenges
      • Dearth of awareness and required infrastructural facilities
  • Market Segmentation Analysis
    • Technology: Advances in Polymerase Chain Reaction technique
    • Application: Diverse applications of pharmacogenomics across industries
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Pharmacogenomics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Pharmacogenomics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

SOPHiA GENETICS Announces Expansion of Work with CHU de Nimes

SOPHiA GENETICS, a pioneer in cloud-native software for data-driven medicine, announces the extension of its collaboration with CHU de Nimes, a regional and university hospital in southern France. This partnership leverages the SOPHiA DDM Platform to enhance pharmacogenomics research, aimed at understanding the impact of genetic profiles on medication efficacy. This collaboration underscores the growing importance of precision medicine, providing CHU de Nimes with advanced tools for drug response research, thereby fostering individualized treatment plans for the French patient populace. [Published On: 2023-11-30]

Diatech Pharmacogenetics Announces New Collaboration to Advance Precision Testing in Oncology

Diatech Pharmacogenetics, a European entity in precision medicine, has embarked on a pivotal collaboration with Janssen Pharmaceutica NV to revolutionize patient care in bladder cancer through enhanced access to precision medicine. Specializing in the research and manufacture of In Vitro Diagnostic (IVD) tests across oncology, Diatech is at the forefront of developing innovative diagnostic tools that identify critical gene alterations, thereby facilitating the administration of targeted therapies. Amidst a growing landscape of targeted drug development aimed at managing and potentially curing various cancers, Diatech's initiative focuses on creating a novel molecular test tailored for bladder cancer [Published On: 2023-06-20]

MyRx launches to provide virtual pharmacogenetic testing consultations

The innovative MyRx service, launched by the University of Florida College of Pharmacy, offers a groundbreaking approach for patients to interpret their pharmacogenetic test outcomes, enhancing medication efficacy significantly. MyRx simplifies the complexity of pharmacogenetic testing, which is crucial for tailoring treatment plans for issues such as depression, anxiety, pain management, and cardiovascular health. [Published On: 2023-02-27]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Pharmacogenomics Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Pharmacogenomics Market, highlighting leading vendors and their innovative profiles. These include Admera Health, Agena Biosciences Inc. by Mesa Laboratories, Inc., BiogeniQ Inc., Castle Biosciences, Inc., CENTOGENE N.V., Coriell Life Sciences, Diatech Pharmacogenetics, Dynamic DNA Laboratorie, Empire Genomics by Biocare Medical, Exceltox Laboratories, Genelex Corporation by Invitae, Genetworx, Genomind, GenXys, Gravity Diagnostics, Illunima Inc., Integra Laboratories, Kailos Genetics by healthOme, Myriad Genetics Inc., OneOme LLC, Personalis Inc., Phamatech Inc. by Caris Life Sciences, Quest Diagnostics, Thermo Fisher Scientific Inc., and ViennaLab Diagnostics GmbH by BioVendor Group.

Market Segmentation & Coverage

This research report categorizes the Pharmacogenomics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Consumables
    • Kits & Reagents
    • Services
  • Technology
    • DNA Sequencing
    • Electrophoresis
    • Mass Spectrometry
    • Microarray
    • Polymerase Chain Reaction
  • Indication
    • Neurology
    • Oncology
    • Pain Management
  • Application
    • Clinical Diagnostics Labs
    • Clinical Research & Drug Discovery
    • Personalized Medicine
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of chronic diseases and demand for precision medicine
      • 5.1.1.2. Increasing investments for healthcare infrastructures
      • 5.1.1.3. Technological advancements associated with molecular diagnostics procedure
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with research and development proficiencies
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging trend of personalized medicines and direct-to-consumer genetic testing services
      • 5.1.3.2. Rising investment in R&D activities to improve pharmacogenomics
    • 5.1.4. Challenges
      • 5.1.4.1. Dearth of awareness and required infrastructural facilities
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Advances in Polymerase Chain Reaction technique
    • 5.2.2. Application: Diverse applications of pharmacogenomics across industries
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Pharmacogenomics Market, by Product

  • 6.1. Introduction
  • 6.2. Consumables
  • 6.3. Kits & Reagents
  • 6.4. Services

7. Pharmacogenomics Market, by Technology

  • 7.1. Introduction
  • 7.2. DNA Sequencing
  • 7.3. Electrophoresis
  • 7.4. Mass Spectrometry
  • 7.5. Microarray
  • 7.6. Polymerase Chain Reaction

8. Pharmacogenomics Market, by Indication

  • 8.1. Introduction
  • 8.2. Neurology
  • 8.3. Oncology
  • 8.4. Pain Management

9. Pharmacogenomics Market, by Application

  • 9.1. Introduction
  • 9.2. Clinical Diagnostics Labs
  • 9.3. Clinical Research & Drug Discovery
  • 9.4. Personalized Medicine

10. Americas Pharmacogenomics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Pharmacogenomics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Pharmacogenomics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. SOPHiA GENETICS Announces Expansion of Work with CHU de Nimes
    • 13.3.2. Diatech Pharmacogenetics Announces New Collaboration to Advance Precision Testing in Oncology
    • 13.3.3. MyRx launches to provide virtual pharmacogenetic testing consultations
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. PHARMACOGENOMICS MARKET RESEARCH PROCESS
  • FIGURE 2. PHARMACOGENOMICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. PHARMACOGENOMICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. PHARMACOGENOMICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. PHARMACOGENOMICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PHARMACOGENOMICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PHARMACOGENOMICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACOGENOMICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DNA SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DNA SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY ELECTROPHORESIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY ELECTROPHORESIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CLINICAL RESEARCH & DRUG DISCOVERY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CLINICAL RESEARCH & DRUG DISCOVERY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 59. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 60. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 67. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 68. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 73. CANADA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 74. CANADA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 75. CANADA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 76. CANADA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 81. MEXICO PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 82. MEXICO PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 83. MEXICO PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 84. MEXICO PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 91. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 92. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 93. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 94. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 110. AUSTRALIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 112. AUSTRALIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 117. CHINA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 118. CHINA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 119. CHINA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 120. CHINA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 125. INDIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 126. INDIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 127. INDIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 128. INDIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 133. INDONESIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 134. INDONESIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 135. INDONESIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 136. INDONESIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 141. JAPAN PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 142. JAPAN PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 143. JAPAN PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 144. JAPAN PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 149. MALAYSIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 150. MALAYSIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 151. MALAYSIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 152. MALAYSIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 158. PHILIPPINES PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 160. PHILIPPINES PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 165. SINGAPORE PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 166. SINGAPORE PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 167. SINGAPORE PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 168. SINGAPORE PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 174. SOUTH KOREA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 176. SOUTH KOREA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 181. TAIWAN PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 182. TAIWAN PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 183. TAIWAN PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 184. TAIWAN PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 189. THAILAND PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 190. THAILAND PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 191. THAILAND PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 192. THAILAND PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 197. VIETNAM PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 198. VIETNAM PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 199. VIETNAM PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 200. VIETNAM PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 215. DENMARK PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 216. DENMARK PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 217. DENMARK PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 218. DENMARK PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 223. EGYPT PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 224. EGYPT PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 225. EGYPT PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 226. EGYPT PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 231. FINLAND PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 232. FINLAND PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 233. FINLAND PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 234. FINLAND PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 239. FRANCE PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 240. FRANCE PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 241. FRANCE PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 242. FRANCE PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 247. GERMANY PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 248. GERMANY PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 249. GERMANY PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 250. GERMANY PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 255. ISRAEL PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 256. ISRAEL PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 257. ISRAEL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 258. ISRAEL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 263. ITALY PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 264. ITALY PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 265. ITALY PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 266. ITALY PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 272. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 274. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 279. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 280. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 281. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 282. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 285. NORWAY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 286. NORWAY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 287. NORWAY PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 288. NORWAY PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 289. NORWAY PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 290. NORWAY PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 293. POLAND PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 294. POLAND PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 295. POLAND PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 296. POLAND PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 297. POLAND PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 298. POLAND PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 299. QATAR PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 300. QATAR PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 301. QATAR PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 302. QATAR PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 303. QATAR PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 304. QATAR PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 305. QATAR PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 306. QATAR PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 307. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 308. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 309. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 310. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 311. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 312. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 313. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 314. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 316. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 318. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 320. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 321. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 322. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 324. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 326. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 327. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 328. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 329. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 330. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 331. SPAIN PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 332. SPAIN PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 333. SPAIN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 334. SPAIN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 335. SPAIN PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 336. SPAIN PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 337. SPAIN PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 338. SPAIN PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 339. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 340. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 341. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 342. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 343. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 344. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 345. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 346. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 348. SWITZERLAND PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 349. SWITZERLAND PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 350. SWITZERLAND PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 351. SWITZERLAND PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 352. SWITZERLAND PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 353. SWITZERLAND PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 354. SWITZERLAND PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 355. TURKEY PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 356. TURKEY PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 357. TURKEY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 358. TURKEY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 359. TURKEY PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 360. TURKEY PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 361. TURKEY PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 362. TURKEY PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 363. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 364. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 365. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 366. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 367. UNITED ARAB EMIRATES PHARMACOGENOM